mogamulizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 5031 1159266-37-1

Description:

MoleculeDescription

Synonyms:

  • mogamulizumab-kpkc
  • AMG-761
  • KM8761
  • mogamulizumab
  • mogamulizumab (genetical recombination)
  • poteligeo
  • KW-0761
a defucosylated humanized anti-CCR4 antibody under phase I clinical trials (2010)
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Aug. 8, 2018 FDA KYOWA KIRIN
March 30, 2012 PMDA Kyowa Hakko Kirin Co., Ltd.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diffuse large B-cell lymphoma 59.60 58.97 13 226 7357 34949335

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diffuse large B-cell lymphoma 55.74 50.22 13 427 12136 79731812
Peripheral T-cell lymphoma unspecified stage III 51.19 50.22 5 435 7 79743941

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FX09 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Other monoclonal antibodies and antibody drug conjugates
FDA CS M0001357 Antibodies, Monoclonal
MeSH PA D000970 Antineoplastic Agents
FDA EPC N0000193863 Monoclonal Antibody
FDA EPC N0000193866 Chemokine Receptor Type 4 Interaction
FDA MoA N0000193867 Chemokine Receptor Type 4 Interactions

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Peripheral T-cell lymphoma indication 109977009
Mycosis fungoides indication 118618005
Primary cutaneous T-cell lymphoma indication 400122007




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
C-C chemokine receptor type 4 GPCR ANTIBODY BINDING SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
YI437801BE UNII
4037780 VANDF
4037781 VANDF
C2987603 UMLSCUI
CHEMBL1743041 ChEMBL_ID
D09761 KEGG_DRUG
DB12498 DRUGBANK_ID
9374 INN_ID
C549035 MESH_SUPPLEMENTAL_RECORD_UI
6477 IUPHAR_LIGAND_ID
2054068 RXNORM
287441 MMSL
34735 MMSL
34736 MMSL
d08855 MMSL
017677 NDDF
773521007 SNOMEDCT_US
773522000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
POTELIGEO HUMAN PRESCRIPTION DRUG LABEL 1 42747-761 INJECTION 4 mg INTRAVENOUS BLA 27 sections
POTELIGEO HUMAN PRESCRIPTION DRUG LABEL 1 42747-761 INJECTION 4 mg INTRAVENOUS BLA 27 sections
POTELIGEO HUMAN PRESCRIPTION DRUG LABEL 1 42747-761 INJECTION 4 mg INTRAVENOUS BLA 27 sections